News
Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...
Illumina estimates about $85 million in costs this year related to tariffs on its DNA sequencing products, the company said ...
Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its ...
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...
The AI-focused biotech insitro has laid off 22% of its workforce, the company said in a Thursday statement. Founded ...
Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...
BMS commits $40B for US expansion, Shionogi buys Torii Pharma for $1.05B, Bavarian Nordic extends BARDA deal, multiple ...
Vor Bio, founded by famed cancer biologist Siddhartha Mukherjee, is looking for a way out. Its decision to pursue strategic ...
'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis
Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...
Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...
President Trump met with pharma CEOs at the White House. After praising investments, a 'most favored nation' drug pricing ...
A federal court handed the FDA and Eli Lilly a major win in a case challenging the end of the tirzepatide shortage.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results